Stockreport

Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial [Yahoo! Finance]

Bicara Therapeutics Inc.  (BCAX) 
PDF enrollment by end-2026 and an interim analysis by mid-2027 with a potential early-2028 launch. Long-term ASCO 2025 data showed a 54% confirmed response rate (21% compl [Read more]